What Opsumit Treats: Main Uses and Benefits

Opsumit (macitentan) is a prescription medicine commonly used for the long-term management of Pulmonary Arterial Hypertension (PAH). It contributes to the management of the condition and its manifestations. The medication is applied in instances where additional symptomatic support is needed in adults and children (aged 2 years and older) who have PAH with symptomatic limitations.

This medication is relevant for easing the overall symptomatic burden in conditions presenting with idiopathic, heritable, or connective tissue disease-associated PAH. The primary therapeutic purpose is relevant for managing symptoms associated with acute or episodic changes that may intensify temporarily.

Management of Symptom Progression and Associated Strain

This medication is applied in addressing symptoms that interfere with daily functioning, with the goal of managing symptoms that create noticeable physiological strain. It is considered relevant for easing the overall symptomatic burden that may lead to episodes of heightened symptoms and may contribute to supporting general well-being during symptomatic phases.

Easing of Functional Symptoms and Daily Comfort

Opsumit is commonly used to help with symptom clusters that interfere with daily functioning, specifically shortness of breath and fatigue that occur during physical effort. By supporting the handling of these distressing manifestations, the medication may assist with maintaining functional stability and a sense of ease. It assists with maintaining functional stability during symptomatic periods.

---

Quick Fact: Relief for Exertional Symptoms
Opsumit contributes to easing the symptom load associated with physical effort, such as undue fatigue and dyspnea (shortness of breath).

Regulatory References

1. European Medicines Agency therapeutic overview

Eligibility Profile: Who Can and Cannot Use Opsumit?

The official eligibility profile for Opsumit (macitentan) is defined by regulatory agencies based on specific population characteristics and pre-existing conditions.

---

Contraindicated Populations

Opsumit must not be used in the following groups, as per official labeling:

• Pregnant females due to the serious risk of fetal harm (embryo-fetal toxicity).
• Females of reproductive potential who are not using reliable contraceptive methods. Strict, mandatory risk management programs (such as REMS) govern use in this population.
• Patients with a history of hypersensitivity to macitentan or any component of the formulation.
• Patients with severe hepatic impairment or those with a high baseline level of liver enzymes (AST and/or ALT > 3 imes the Upper Limit of Normal).
• Breastfeeding women.

---

Populations with Restricted or Conditional Use

Treatment is not recommended or requires caution in other specific populations:

• Patients with severe anemia.
• Patients with moderate hepatic impairment.
• Patients undergoing dialysis (end-stage renal disease) or those with severe renal impairment.
• Pediatric patients below two years of age (use not established).

Adults and, in some regions, pediatric patients aged 2 years and older, are within the eligible age group for treatment, provided they do not meet any contraindicated criteria.

The official regulatory profile for Opsumit (macitentan) details specific constraints regarding co-administration with other therapeutic agents and substances. Co-administration is formally contraindicated with Sparsentan due to the documented risk of pharmacodynamic synergism, and with Guanylate Cyclase (GC) Stimulators.

The most significant restrictions relate to metabolic enzyme interactions. Strong CYP3A4 inhibitors, such as ketoconazole and ritonavir, are officially documented to increase macitentan systemic exposure by approximately twofold; therefore, co-administration with these agents must be avoided.

Conversely, strong CYP3A4 inducers, including rifampin and the herbal product St. John's Wort, substantially reduce macitentan exposure, causing up to a 79% decrease in the Area Under the Curve (AUC), and their concomitant use must also be avoided. Furthermore, co-administration with moderate dual inhibitors of CYP3A4 and CYP2C9 (e.g., fluconazole) is restricted, as regulatory models predict an approximate four-fold increase in macitentan exposure.

Regarding other pathways, the official data indicates that macitentan is not expected to have clinically relevant interactions with drug transporters such as P-glycoprotein (P-gp) or Organic Anion Transporting Polypeptides (OATPs). Finally, the regulatory information confirms that macitentan can be administered irrespective of food intake, as no food-drug pharmacokinetic interaction is documented.

️ How Opsumit Works

Opsumit (macitentan) is a medication that works by providing dual, sustained antagonism against the endogenous vasoconstrictor peptide Endothelin-1 ( ET-1) in the pulmonary arteries.

---

Targeted Dual Blockade of Vasoconstriction Signaling

This domain covers the primary molecular interaction: Macitentan blocks the activation of both the mathbfETmathbfA and mathbfETmathbfB receptors, which transmit the ET-1 signal for vasoconstriction. By continuously preventing the binding of ET-1 to these receptors, the drug suppresses acute muscle contraction and results in the modulation of vascular tone and sustained pulmonary vasodilation.

---

Modulation of Pathological Vascular Remodeling Signals

This mechanism focuses on modulating the chronic, structural changes within the pulmonary artery walls. Blockade of the mathbfETmathbfA receptor specifically inhibits the ET-1 driven signals that promote smooth muscle cell proliferation and growth. This action modulates the signaling that promotes the thickening and narrowing of the vessel lumen. This modulation contributes to a decrease in Pulmonary Vascular Resistance (PVR), affecting the afterload on the Right Ventricle.

How to Use Opsumit (Macitentan)

The use of Opsumit follows specific protocols regarding the method of administration, dose, and frequency.

Route and Frequency

The medicine is taken orally, once daily.

Official Dosing and Administration

Patient Population	Dosage Form	Dosing Regimen
Adults and Pediatric Patients ( 40 kg )	10 mg film-coated tablet	10 mg once daily
Pediatric Patients ( < 40 kg )	2.5 mg dispersible tablet	Weight-based dosing

---

Administration Requirements

1. Timing and Meals: The medicine should be taken at approximately the same time each day and may be taken with or without food.
2. 10 mg Tablets: The film-coated tablet must be swallowed whole with water. It is not recommended to break the tablet.
3. 2.5 mg Dispersible Tablets: These are intended for use as an oral suspension, prepared by dispersing the tablet in room temperature liquids.

Missed Dose Instructions

If a dose is missed, the patient should take the missed dose as soon as possible. Patients are instructed not to take two doses at the same time to make up for the missed dose, but to take the next scheduled dose at the regular time.

Population-Specific Constraints

• Hepatic Impairment: Use is generally not recommended in patients with moderate or severe liver impairment.
• Reproductive Management: For females of reproductive potential, effective contraception must be used during treatment and for one month after stopping the medicine, and regular pregnancy testing is required.

Research evidence / Overview of Studies for Opsumit

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research on Opsumit (macitentan) has been conducted to explore how it is studied for the long-term management of Pulmonary Arterial Hypertension (PAH). The most detailed evidence comes from long-term randomized controlled trials (RCTs). These pivotal studies involved adults and adolescents with symptomatic PAH, including those whose condition was tied to connective tissue disease or idiopathic causes. Many participants were both newly diagnosed and those already receiving treatment.

Researchers primarily examined the time until the first occurrence of a composite morbidity/mortality event. This key measure included severe outcomes such as hospitalization due to PAH, the need for more intensive treatment, or death. Trials also monitored outcomes related to physical discomfort, specifically by measuring changes in the 6-Minute Walk Distance (6MWD), which is used in research exploring how symptoms change over time and reflects outcomes related to daily functioning or activity level.

Studies reported data show patterns related to the monitored composite event rate over a median patient observation period of more than two years. Additionally, research reported changes measured during the study period in the average 6MWD scores. Findings were observed in some studies to be consistent across the different types of PAH studied.

---

Evidence for Use in Portopulmonary Hypertension (PoPH)

Research has also was studied for the more specific patient group with Portopulmonary Hypertension (PoPH), where PAH is associated with portal hypertension or liver disease. Studies conducted for this condition include a dedicated, smaller randomized controlled trial (RCT), which focused on a shorter observation period.

This research examined outcomes related to systemic or functional imbalance, primarily focusing on hemodynamic parameters. Specifically, the RCT's primary goal was to measure the change in Pulmonary Vascular Resistance (PVR). The short-term RCT reported measurements of PVR findings, but research findings were mixed for functional outcomes like 6MWD measured during the study period.

---

What is Still Uncertain About Opsumit Research

Several areas in the research landscape for Opsumit remain uncertain or are still emerging. Research findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. The key long-term clinical trial relied heavily on a composite endpoint rather than focusing solely on all-cause mortality, meaning the independent effect on survival is not fully established. Also, comparative evidence is lacking for many direct, head-to-head comparisons against other available PAH therapies. Data for certain groups, such as those with advanced cirrhosis, remain insufficient for broader characterization.

Common questions about Opsumit (FAQ)

---

Q: What is the clinical goal of treatment with Opsumit?

A: According to official regulatory information, Opsumit is indicated for the treatment of Pulmonary Arterial Hypertension (PAH), which is categorized as WHO Group I. The primary goal of treatment is to help reduce the risk of serious events related to the disease getting worse or requiring hospitalization for PAH. Opsumit may be used as a standalone treatment or in combination with other medications for PAH.

Q: How long will I need to be on effective contraception after stopping Opsumit?

A: Due to the risk of fetal harm, effective contraception is to be used by females of reproductive potential, as outlined in the risk management plan. Official product information states that this protection must be continued for one month after stopping the use of Opsumit.

Q: What is the active ingredient in Opsumit?

A: Opsumit is a specialized prescription medicine, and its sole active component is macitentan. This information is confirmed in the official drug description section of the regulatory labeling.

Q: What is the shelf life of Opsumit tablets before they expire?

A: Official regulatory documents indicate that the shelf life for Opsumit is 5 years from the date of manufacture. This shelf life applies when the tablets are stored correctly in their original packaging at the controlled room temperature specified on the label.

Q: What should I do if I experience shortness of breath or chest pain while taking Opsumit?

A: Regulatory warnings indicate that symptoms such as unexpected or increasing shortness of breath, swelling, or signs of serious conditions like fluid retention or liver injury are to be reported to the treating physician for evaluation. While on Opsumit, there is a rare risk of developing pulmonary edema (fluid in the lungs), and any concerning symptoms should be medically assessed right away.

Q: What type of specialist typically prescribes and manages treatment with Opsumit?

A: Official prescribing information states that Opsumit is intended to be initiated and monitored under the care of a physician experienced in the treatment of Pulmonary Arterial Hypertension (PAH). This practice helps ensure appropriate management and oversight of this specialized condition.

Q: How will my doctor monitor my safety while I'm on Opsumit?

A: Regulatory documents require certain safety monitoring tests to be performed while on this medicine. This typically includes liver enzyme tests (ALT and AST) prior to and monthly during treatment. They also require the measurement of hemoglobin levels before and during treatment as clinically indicated. Additionally, monthly pregnancy tests are required for females who are able to become pregnant.

How to Store and Dispose of Opsumit

Opsumit (macitentan) tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and should not be frozen or exposed to excessive heat or moisture, as stated in the official regulatory labeling.

Child Safety and Disposal

It is mandatory to keep Opsumit out of the reach and sight of children.

For disposal, follow official guidelines for unused or expired medicine. Opsumit is included on the FDA flush list, meaning it can be flushed down the toilet if a drug take-back program is not readily available. Otherwise, dispose of the medicine according to approved household trash procedures, such as mixing it with an unappealing substance and sealing it in a container.